The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.
5‐HT 2A and α1b‐adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants
Abstract
Addictive properties of drugs of misuse are generally considered to be mediated by an increased release of dopamine (DA) in the ventral striatum. However, recent experiments indicated an implication of alpha1b-adrenergic receptors in behavioural responses to psychostimulants and opiates. We show now that DA release induced in the ventral striatum by morphine (20 mg/kg) is completely blocked by prazosin (1 mg/kg), an alpha1-adrenergic antagonist. However, morphine-induced increases in DA release in the ventral striatum were found to be similar in mice deleted for the alpha1b-adrenergic receptor (alpha1b-AR KO) and in wild-type (WT) mice, suggesting the presence of a compensatory mechanism. This acute morphine-evoked DA release was completely blocked in alpha1b-AR KO mice by SR46349B (1 mg/kg), a 5-HT2A antagonist. SR46349B also completely blocked, in alpha1b-AR KO mice, the locomotor response and the development of behavioural sensitization to morphine (20 mg/kg) and D-amphetamine (2 mg/kg). Accordingly, the concomitant blockade of 5-HT2A and alpha1b-adrenergic receptors in WT mice entirely blocked acute locomotor responses but also the development of behavioural sensitization to morphine, D-amphetamine or cocaine (10 mg/kg). We observed, nevertheless, that inhibitory effects of each antagonist on locomotor responses to morphine or D-amphetamine were more than additive (160%) in naïve WT mice but not in those sensitized to either drug. Because of these latter data and the possible compensation by 5-HT2A receptors for the genetic deletion of alpha1b-adrenergic receptors, we postulate the existence of a functional link between these receptors, which vanishes during the development of behavioural sensitization.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDMA also strongly affects 5-HT2A receptors, which are important mediators of behavioral sensitization (47–49).”
Citations
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859
The neural basis of drug craving: An incentive-sensitization theory of addiction
Robinson, T. (1993) · Brain Research Reviews · doi:10.1016/0165-0173(93)90013-p · Cited by 7,346
Robinson, T. G., & BECKER, J. (1986) · Brain Research · doi:10.1016/s0006-8993(86)80193-7 · Cited by 2,108
Wise, R. A., & Rompre, P.-P. (1989) · Annual Review of Psychology · doi:10.1146/annurev.ps.40.020189.001203 · Cited by 1,968
Pazos, Á., & Palacios, J. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)90856-x · Cited by 1,855
Kelly, P. H., Seviour, P. W., & Iversen, S. D. (1975) · Brain Research · doi:10.1016/0006-8993(75)90233-4 · Cited by 1,740
Opioids excite dopamine neurons by hyperpolarization of local interneurons
Johnson, S., & North, R. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00483.1992 · Cited by 1,637
Addiction, Dopamine, and the Molecular Mechanisms of Memory
Berke, J. D., & Hyman, S. E. (2000) · Neuron · doi:10.1016/s0896-6273(00)81056-9 · Cited by 1,184
Pazos, Á., Cortés, R., & Palacios, J. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)90857-1 · Cited by 824
Sesack, S. R., & Pickel, V. M. (1992) · Journal of Comparative Neurology · doi:10.1002/cne.903200202 · Cited by 820
Cited by
Sorted by citations
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission
Alex, K. D., & Pehek, E. A. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.004 · Cited by 658
Opponency revisited: competition and cooperation between dopamine and serotonin
Boureau, Y.-L., & Dayan, P. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.151 · Cited by 456
Goodman, A. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.030 · Cited by 445
The role of serotonin 5-HT2A receptors in memory and cognition
Zhang, G., & Stackman, R. W. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00225 · Cited by 398
There and Back Again: A Tale of Norepinephrine and Drug Addiction
Weinshenker, D., & Schroeder, J. P. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301263 · Cited by 347
The role of serotonin in drug use and addiction
Müller, C. P., & Homberg, J. R. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.04.007 · Cited by 345
Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
Snyder, G. L., Vanover, K. E., Zhu, H., Miller, D. B., O'Callaghan, J. P., Tomesch, J., Li, P., Zhang, Q., Krishnan, V., Hendrick, J. P., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3704-1 · Cited by 293
López‐Arnau, R., Martínez-Clemente, J., Pubill, D., Escubedo, E., & Camarasa, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01998.x · Cited by 196
Modulating the Neuromodulators: Dopamine, Serotonin, and the Endocannabinoid System
Peters, K. Z., Cheer, J. F., & Tonini, R. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2021.02.001 · Cited by 180
Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse
Bubar, M. J., & Cunningham, K. A. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00916-3 · Cited by 139
Pothakos, K., Kurz, M. J., & Lau, Y.-S. (2009) · BMC Neuroscience · doi:10.1186/1471-2202-10-6 · Cited by 134
Schank, J. R., Ventura, R., Puglisi‐Allegra, S., Alcaro, A., Cole, C. D., Liles, L. C., Seeman, P. M., & Weinshenker, D. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301000 · Cited by 129
Adriani, W., Leo, D., Greco, D., Rea, M., di Porzio, U., Laviola, G., & Perrone‐Capano, C. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300962 · Cited by 133
Role of Noradrenergic Signaling by the Nucleus Tractus Solitarius in Mediating Opiate Reward
Olson, V. G., Heusner, C. L., Bland, R. J., During, M. J., Weinshenker, D., & Palmiter, R. D. (2006) · Science · doi:10.1126/science.1119311 · Cited by 126
Salomon, L., Lanteri, C., Glowinski, J., & Tassin, J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600839103 · Cited by 117
Self-citationThe α1-adrenergic receptors: diversity of signaling networks and regulation
Cotecchia, S. (2010) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2010.518152 · Cited by 110
Self-citationMechanisms of Disulfiram-induced Cocaine Abstinence: Antabuse and Cocaine Relapse
Gaval‐Cruz, M., & Weinshenker, D. (2009) · Molecular Interventions · doi:10.1124/mi.9.4.6 · Cited by 114
Navailles, S., Moison, D., Cunningham, K. A., & Spampinato, U. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301414 · Cited by 110
Ninkovic, J., Folchert, A., Makhankov, Y. V., Neuhauss, S. C. F., Sillaber, I., Strähle, U., & Bally‐Cuif, L. (2006) · Journal of Neurobiology · doi:10.1002/neu.20231 · Cited by 101
Lanteri, C., Salomon, L., Torrens, Y., Glowinski, J., & Tassin, J. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301548 · Cited by 95
Self-citationNK 1 (TACR 1 ) receptor gene ‘knockout’ mouse phenotype predicts genetic association with ADHD
Yan, T., McQuillin, A., Thapar, A., Asherson, P. J., Hunt, S. P., Stanford, S. C., & Gurling, H. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108100255 · Cited by 99
Mitrano, D. A., Schroeder, J. P., Smith, Y., Cortright, J. J., Bubula, N., Vezina, P., & Weinshenker, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.68 · Cited by 94
Tassin, J. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.038 · Cited by 91
Self-citationTrigo, J. M., Renoir, T., Lanfumey, L., Hamon, M., Lesch, K., Robledo, P., & Maldonado, R. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.005 · Cited by 91
Endogenous opiates and behavior: 2004
Bodnar, R. J., & Klein, G. E. (2005) · Peptides · doi:10.1016/j.peptides.2005.06.010 · Cited by 86
Ferrucci, M., Limanaqi, F., Ryskalin, L., Biagioni, F., Busceti, C. L., & Fornai, F. (2019) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2019.00048 · Cited by 91
Adrenaline Rush: The Role of Adrenergic Receptors in Stimulant-Induced Behaviors
Schmidt, K. T., & Weinshenker, D. (2014) · Molecular Pharmacology · doi:10.1124/mol.113.090118 · Cited by 81
Neuronal pathways linking substance P to drug addiction and stress
Commons, K. G. (2009) · Brain Research · doi:10.1016/j.brainres.2009.11.014 · Cited by 73
Masana, M., Bortolozzi, A. A., & Artigas, F. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000908 · Cited by 78
Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review
Divito, A. J., & Leger, R. F. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-06009-x · Cited by 78
Glennon, R. A. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-420118-7.00015-9 · Cited by 71
The serotonin 5-HT 2C receptor and the non-addictive nature of classic hallucinogens
Canal, C. E., & Murnane, K. S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677104 · Cited by 73
Zayara, A. E., McIver, G., Valdivia, P. N., Lominac, K. D., McCreary, A. C., & Szumlinski, K. K. (2011) · Psychopharmacology · doi:10.1007/s00213-010-1996-3 · Cited by 64
Pharmacological models of ADHD
Kostrzewa, R. M., Kostrzewa, R. A., Kostrzewa, R. A., Nowak, P. G., & Brus, R. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0826-1 · Cited by 61
Pascoli, V., Valjent, E., Corbillé, A.-G., Corvol, J.-C., Tassin, J.-P., Girault, J.-A., & Hervé, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.011809 · Cited by 59
Self-citationPerez, D. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.652152 · Cited by 63
Yan, T. C., Hunt, S. P., & Stanford, S. C. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.021 · Cited by 58
Rommelfanger, K. S., Mitrano, D. A., Smith, Y., & Weinshenker, D. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.11.019 · Cited by 55
Serotonin (5-hydroxytryptamine) 5-HT2A receptor
Anastasio, N. C., Stoffel, E. C., Fox, R. G., Bubar, M. J., Rice, K. C., Moeller, F. G., & Cunningham, K. A. (2011) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e328345f90d · Cited by 52
Behavioral genetic contributions to the study of addiction-related amphetamine effects
Phillips, T. J., Kamens, H. M., & Wheeler, J. M. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.10.008 · Cited by 51
Mirtazapine prevents induction and expression of cocaine-induced behavioral sensitization in rats
Salazar‐Juárez, A., Barbosa-Méndez, S., Jurado, N., Hernández-Miramontes, R., Leff, P., & Antón, B. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.02.010 · Cited by 49
The Effects of Locus Coeruleus and Norepinephrine in Methamphetamine Toxicity
Ferrucci, M., Giorgi, F. S., Bartalucci, A., Busceti, C. L., & Fornai, F. (2013) · Current Neuropharmacology · doi:10.2174/157015913804999522 · Cited by 47
Egerton, A., Ahmad, R., Hirani, E., & Grasby, P. M. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1226-4 · Cited by 49
Presynaptic Metabotropic Receptors for Acetylcholine and Adrenaline/Noradrenaline
Gilsbach, R., & Hein, L. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-74805-2_9 · Cited by 47
Bayassi-Jakowicka, M., Lietzau, G., Czuba, E., Steliga, A., Waśkow, M., & Kowiański, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189806 · Cited by 43
Ago, Y., Nakamura, S., Baba, A., & Matsuda, T. (2008) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fm0070121 · Cited by 44
Alpha‐Noradrenergic Receptors Modulate the Development and Expression of Cocaine Sensitization
Jiménez‐Rivera, C. A., Feliú-Mójer, M. I., & Vázquez‐Torres, R. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1369.039 · Cited by 42
Jîtcă, G., Ősz, B. E., Tero-Vescan, A., & Vari, C.-E. (2021) · Antioxidants · doi:10.3390/antiox10030381 · Cited by 44
Pang, G., Wu, X. G., Tao, X., Mao, R., Liu, X., Zhang, Y.-M., Li, G., Stackman, R. W., Dong, L., & Zhang, G. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00514 · Cited by 41
Desjardins, S., Belkaï, E., Crété, D., Cordonnier, L., Scherrmann, J., Noble, F., & Cynthia Marie-claire, A. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.027 · Cited by 39
Novel pharmacotherapeutic targets for the management of drug addiction
Heidbreder, C. A. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.09.038 · Cited by 38
Transgenic mice in the study of drug addiction and the effects of psychostimulant drugs
Sora, I., Li, B., Igari, M., Hall, F. S., & Ikeda, K. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05276.x · Cited by 38
Noradrenergic circuits and signaling in substance use disorders
Downs, A. M., & McElligott, Z. A. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108997 · Cited by 37
Orejarena, M. J., Lanfumey, L., Maldonado, R. J., & Robledo, P. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001215 · Cited by 38
Zaniewska, M., McCreary, A. C., & Filip, M. (2009) · Synapse · doi:10.1002/syn.20645 · Cited by 35
The Involvement of Norepinephrine in Behaviors Related to Psychostimulant Addiction
Zaniewska, M., Filip, M., & Przegaliński, E. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150121225659 · Cited by 35
Ago, Y., Nakamura, S., Kajita, N., Uda, M., Hashimoto, H., Baba, A., & Matsuda, T. (2007) · Synapse · doi:10.1002/syn.20421 · Cited by 34
Alsene, K. M., Fallace, K., & Bakshi, V. P. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.106 · Cited by 34
Chen, Z., Lin, Y., Zhou, Q., Shilin, X., Li, C., Lin, R., Li, J., Chen, Y., Luo, C., & Mo, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112935 · Cited by 35
Schmidt, K. T., Schroeder, J. P., Foster, S. L., Squires, K. E., Smith, B. M., Pitts, E. G., Epstein, M. P., & Weinshenker, D. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.005 · Cited by 33
Purkayastha, S., Ford, J. R., Kanjilal, B., Diallo, S., Inigo, J. D. R., Neuwirth, L. S., Idrissi, A. E., Ahmed, Z., Wieraszko, A., Azmitia, E. C., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07565.x · Cited by 32
Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use
Stevens, M. W., Stevens, M. W., Stevens, M. W., Stevens, M. W., Tawney, R., Tawney, R., Tawney, R., Tawney, R. L., West, C. M., West, C. M., et al. (2013) · mAbs · doi:10.4161/mabs.27620 · Cited by 32
The Effects of Methylphenidate on Knockin Mice with a Methylphenidate-Resistant Dopamine Transporter
Tilley, M. R., & Gu, H. H. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.141713 · Cited by 32
The renaissance in psychedelic research: What do preclinical models have to offer
Murnane, K. S. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.08.003 · Cited by 35
Ding, Z., Toalston, J. E., Oster, S. M., McBride, W. J., & Rodd, Z. A. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1468-9 · Cited by 31
Zaniewska, M., McCreary, A. C., Wydra, K., & Filip, M. (2010) · Synapse · doi:10.1002/syn.20756 · Cited by 31
Lanteri, C., Hernàndez-Vallejo, S. J., Salomon, L., Doucet, E. L., Godeheu, G., Torrens, Y., Houades, V., & Tassin, J. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3315-08.2009 · Cited by 34
Self-citationChemical Composition and Biological Uses of Artemisia absinthium (Wormwood)
Bhat, R. R., Rehman, M. U., Shabir, A., Mir, M. R., Ahmad, A., Khan, R., Masoodi, M. H., Madkhali, H. A., & Ganaie, M. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-04408-4_3 · Cited by 29
Villégier, A., Lotfipour, S., Belluzzi, J. D., & Leslie, F. M. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0799-7 · Cited by 29
Paradoxical constitutive behavioral sensitization to amphetamine in mice lacking 5-HT2A receptors
Salomon, L., Lanteri, C., Godeheu, G., Blanc, G., Gingrich, J. A., & Tassin, J. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0810-3 · Cited by 28
Self-citationKaneko, Y., Kashiwa, A., Ito, T., Ishii, S., Umino, A., & Nishikawa, T. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301111 · Cited by 28
Buck, K., & Ferger, B. (2009) · Synapse · doi:10.1002/syn.20709 · Cited by 26
Involvement of α1-adrenoceptors in conditioned place preference supported by nicotine in rats
Forget, B., Hamon, M., & Thiébot, M.-H. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1559-7 · Cited by 25
Verheij, M. M. M., & Cools, A. R. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04259.x · Cited by 25
(±)-Nantenine analogs as antagonists at human 5-HT2A receptors: C1 and flexible congeners
Chaudhary, S., Pecic, S., LeGendre, O., Navarro, H. A., & Harding, W. W. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.048 · Cited by 25
Łupina, M., Tarnowski, M., Baranowska‐Bosiacka, I., Talarek, S., Listos, P., Kotlinska, J. H., Gutowska, I., & Listos, J. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0993-0 · Cited by 23
Villégier, A., Salomon, L., Blanc, G., Godeheu, G., Glowinski, J., & Tassin, J. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05011.x · Cited by 21
Self-citationStanford, S. C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.03.021 · Cited by 22
Disrupted reinforcement learning during post-error slowing in ADHD
Chevrier, A., Bhaijiwala, M., Lipszyc, J., Cheyne, D., Graham, S., & Schachar, R. (2019) · PLOS ONE · doi:10.1371/journal.pone.0206780 · Cited by 21
Influence of Morphine and Dopamine Receptor Sensitization on Locomotor Activity in Mice
Heidari, P., Sahebgharani, M., Riazi, G. H., & Zarrindast, M. (2006) · Pharmacology · doi:10.1159/000096428 · Cited by 20
Ago, Y., Araki, R., Yano, K., Hiramatsu, N., Kawasaki, T., Chaki, S., Nakazato, A., Onoe, H., Hashimoto, H., Baba, A., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2295-3 · Cited by 19
Neuroprotective effect of wormwood against lead exposure
Kharoubı, O., Slimani, M., & Aoues, A. (2011) · Journal of Emergencies Trauma and Shock · doi:10.4103/0974-2700.76834 · Cited by 19
Gastric pentadecapeptide BPC 157 counteracts morphine-induced analgesia in mice.
Blagaić, A. B., Turčić, P., Blagaić, V., Dubovecak, M., Jelovac, N., Zemba, M., Radić, B., Bečejac, T., Rokotov, D. S., & Sikirić, P. (2009) · PubMed · Cited by 19
Root-Bernstein, R. S., Turke, M. J., Subhramanyam, U. K. T., Churchill, B., & Labahn, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010272 · Cited by 18
Hayes, D. M., Fee, J. R., McCown, T. J., Knapp, D. J., Breese, G. R., Cubero, I., Carvajal, F., Lerma-Cabrera, J. M., Navarro, M., & Thiele, T. E. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00336.x · Cited by 18
Novel 4-phenylpiperidine-2,6-dione derivatives. Ligands for α1-adrenoceptor subtypes
Romeo, G., Materia, L., Modica, M. N., Pittalà, V., Salerno, L., Siracusa, M. A., Manetti, F., Botta, M., & Minneman, K. P. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.03.054 · Cited by 17
Biological Treatments for Amfetamine Dependence
Hill, K. P., & Sofuoglu, M. (2007) · CNS Drugs · doi:10.2165/00023210-200721100-00005 · Cited by 16
Treatment of the Psychostimulant-Sensitized Animal Model of Schizophrenia
Shuto, T., & Nishi, A. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00218.x · Cited by 16
Developing Biomarkers for Methamphetamine Addiction
Mendelson, J. E., Baggott, M. J., Flower, K., & Galloway, G. P. (2011) · Current Neuropharmacology · doi:10.2174/157015911795017128 · Cited by 16
O’Leary, A., Kõiv, K., Raudkivi, K., & Harro, J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.02.003 · Cited by 14
Murnane, K. S., Güner, O. F., Bowen, J. P., Rambacher, K. M., Moniri, N. H., Murphy, T. J., Daphney, C. M., Oppong‐Damoah, A., & Rice, K. C. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.04.003 · Cited by 16
Trovero, F., David, S., Bernard, P., Puech, A. J., Bizot, J., & Tassin, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151242 · Cited by 15
Self-citationProposition d'un modèle neurobiologique de l'addiction
Tassin, J. (2009) · Psychotropes · doi:10.3917/psyt.143.0011 · Cited by 15
Self-citationVelásquez-Martínez, M. C., Santos‐Vera, B., Vélez-Hernández, M. E., Vázquez‐Torres, R., & Jiménez‐Rivera, C. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030790 · Cited by 15
Mpoulimari, I., & Zintzaras, E. (2022) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000316 · Cited by 17
Serotonergic mechanism underlying tranylcypromine enhancement of nicotine self‐administration
Villégier, A., Belluzzi, J. D., & Leslie, F. M. (2010) · Synapse · doi:10.1002/syn.20864 · Cited by 14
Sensitization to the Prosocial Effects of 3,4-Methylenedioxymethamphetamine (MDMA)
Curry, D. W., Berro, L. F., Belkoff, A. R., Sulima, A., Rice, K. C., & Howell, L. L. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.017 · Cited by 13
The Role of Serotonin in Drug Addiction
Müller, C. P., Pum, M. E., Schumann, G., & Huston, J. P. (2010) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(10)70099-0 · Cited by 13
Epistasis between neurochemical gene polymorphisms and risk for ADHD
Segurado, R., Bellgrove, M. A., Manconi, F., Gill, M., & Hawi, Z. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.250 · Cited by 13
Neurobiologie de l'addiction : proposition d'un nouveau concept
Tassin, J. (2007) · L information psychiatrique · doi:10.1684/ipe.2007.0092 · Cited by 13
Self-citation
Metadata
- Authors
- Auclair, A., Drouin, C., Cotecchia, S., Glowinski, J., & Tassin, J.
- Affiliations
- Inserm (FR)
- Corresponding author
- Tassin, Jean‐Pol
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 2004-12
- Volume
- 20
- Issue
- 11
- Pages
- 3073-3084
- ISSN
- 0953-816X (ISSN-L)
- 1460-9568
- OpenAlex
- W2007935614
- Semantic Scholar
- 6e7f99f756cb4e158e01c8c27ae8be88a5eaa920
- Cited by
- 163
- References
- 63
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 5 · 2021: 7 · 2020: 3 · 2019: 8 · 2018: 3 · 2017: 5 · 2016: 10 · 2015: 3 · 2014: 11 · 2013: 3 · 2012: 3
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Servier
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- 5-HT2A receptor, alpha1B-adrenergic receptor, dopamine release, ventral striatum, morphine, prazosin, behavioral sensitization, locomotor response, psychostimulants, cocaine, amphetamine, receptor interaction, compensatory mechanisms
- MeSH terms
- Adrenergic alpha-Antagonists, Central Nervous System Stimulants, Anesthetics, Local, Animals, Behavior, Animal, Brain Chemistry, Cocaine, Corpus Striatum, Dextroamphetamine, Dopamine, Drug Administration Schedule, Drug Interactions, Fluorobenzenes, Male, Motor Activity, Narcotics, Phenols, Prazosin, Serotonin Antagonists, Time Factors, Microdialysis, Receptors, Adrenergic, alpha-1, Mice, Knockout, Receptor, Serotonin, 5-HT2A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review